Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development
Supportive Care in Cancer · 2026-07 · 34 (7)
DOI: 10.1007/s00520-026-10918-1 ↗Kurz gefasst
Scoping Review in der Zeitschrift Supportive Care in Cancer, online erschienen am 20.06.2026. Verfasst von João Daniel de Souza Menezes und 6 weiteren Autor:innen. Beteiligte Einrichtung: FAMERP (Faculdade de Medicina de São José Do Rio Preto), São José Do Rio Preto, Brazil. Hauptthemen laut MEDLINE: Neoplasms, Gastrointestinal Microbiome, Antineoplastic Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculdade De Medicina De São José Do Rio Preto.
Abstract (Originalsprache)
Purpose
This scoping review aimed to systematically map and critically describe the current evidence on the role of the gut microbiome as a biomarker in oncology, including microbiome-based predictive models and microbial signatures associated with treatment response, toxicity and disease course, and to identify methodological gaps and challenges for clinical translation in precision medicine.
Methods
This scoping review was conducted following the Joanna Briggs Institute (JBI) guidelines for scoping reviews and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). The search was performed in five electronic databases (PubMed/MEDLINE, Web of Science, Scopus, SciELO, and LILACS) using a structured PICO strategy. Studies involving adult cancer patients undergoing systemic oncological therapies (including chemotherapy, immunotherapy and combined regimens), with gut microbiome analysis and the investigation, development or validation of microbiome-based biomarkers or predictive models, were included.
Results
The literature demonstrates that specific microbial taxa significantly influence the efficacy of immunotherapies (e.g., AUCs up to 0.88 for ICI response prediction) and chemotherapies, and modulate toxicity (e.g., mucositis reduction from 47.1% to 25% with probiotics). Microbiome-based predictive models often outperform clinical markers (e.g., AUC of 0.88 vs. 0.50 in urothelial carcinoma), and variations in microbiota composition can predict disease progression. The literature mapping of the 20 included studies demonstrates that specific microbial taxa significantly influence the efficacy of immunotherapies (e.g., AUCs up to 0.88 for ICI response prediction) and chemotherapies. Regarding toxicity, while the review focuses on baseline biomarkers, exploratory intervention-based data were addressed, showing that a probiotic cocktail reduced Grade 3–4 oral mucositis from 47.1% to 25%. Furthermore, microbiome-based predictive models demonstrated enhanced discriminatory accuracy in predicting patient outcomes compared to standard clinical classification markers alone (e.g., achieving an Area Under the Curve [AUC] of 0.88 vs. 0.50 for clinical factors in urothelial carcinoma), though these models remain in early exploratory stages.
Conclusion
Overall, the evidence suggests a growing interest and potential for microbiome-based predictive models in oncology; however, their clinical translation remains limited by methodological heterogeneity, insufficient external validation, and incomplete mechanistic understanding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- FAMERP (Faculdade de Medicina de São José Do Rio Preto), São José Do Rio Preto, Brazil.
- FAMERP (Faculdade de Medicina de São José Do Rio Preto), São José Do Rio Preto, Brazil. matheus.querino@edu.famerp.br.
Förderung
- Faculdade De Medicina De São José Do Rio Preto
Zitieren
APA
de Souza Menezes, J. D., da Silva, M. Q., Dos Santos, E. R., de Carvalho, S. R. P. V. T., Faria, M. A. G., de Cássia Helú Mendonça Ribeiro, R., & André, J. C. (2026). Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development. Supportive Care in Cancer, 34(7). https://doi.org/10.1007/s00520-026-10918-1
Vancouver
de Souza Menezes JD, da Silva MQ, Dos Santos ER, de Carvalho SRPVT, Faria MAG, de Cássia Helú Mendonça Ribeiro R, et al. Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development. Supportive Care in Cancer. 2026;34(7). doi:10.1007/s00520-026-10918-1
BibTeX
@article{deSouzaMenezes2026,
author = {de Souza Menezes, João Daniel and da Silva, Matheus Querino and Dos Santos, Emerson Roberto and de Carvalho, Stela Regina Pedroso Vilela Torres and Faria, Mikaell Alexandre Gouvea and de Cássia Helú Mendonça Ribeiro, Rita and André, Júlio César},
title = {Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {7},
doi = {10.1007/s00520-026-10918-1}
}
EUVIMED